Article
Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Hepatology (Baltimore, Md.) - 1 Sept 2013
Seto Wai-Kay, Wong Danny Ka-Ho, Fung James, Huang Fung-Yu, Lai Ching-Lung, Yuen Man-Fung
Abstract excerpt
UNLABELLED: The profile and clinical significance of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleoside analogue (NA) therapy in chronic hepatitis B (CHB) is undetermined. From 1994 to 2002, 322 Chinese CHB patients were started on lamivudine in our center. Patients were recruited if they were continuously treated with lamivudine for at least 10 years and maintained favorable virologic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.